https://www.avient.com/sites/default/files/resources/POL%2520IR%2520Presentation%2520GS%2520w%2520non%2520GAAP%25205_21_14.pdf
They are based on management’s expectations that involve a number of business risks and uncertainties, any of which could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Factors that could cause actual results to differ materially from those implied by these forward-looking statements include, but are not limited to: The final amount of charges resulting from the planned manufacturing realignment and the Company’s ability to realize anticipated savings and operational benefits from the asset realignment; Our ability to achieve the strategic and other objectives relating to the acquisition of Spartech Corporation, including any expected synergies; Our ability to successfully integrate Spartech and achieve the expected results of the acquisition, including, without limitation, the acquisition being accretive; Disruptions, uncertainty or volatility in the credit markets that could adversely impact the availability of credit already arranged and the availability and cost of credit in the future; The financial condition of our customers, including the ability of customers (especially those that may be highly leveraged and those with inadequate liquidity) to maintain their credit availability; The speed and extent of an economic recovery, including the recovery of the housing market; Our ability to achieve new business gains; The effect on foreign operations of currency fluctuations, tariffs, and other political, economic and regulatory risks; Changes in polymer consumption growth rates in the markets where we conduct business; Changes in global industry capacity or in the rate at which anticipated changes in industry capacity come online; Fluctuations in raw material prices, quality and supply and in energy prices and supply; Production outages or material costs associated with scheduled or unscheduled maintenance programs; Unanticipated developments that could occur with respect to contingencies such as litigation and environmental matters; An inability to achieve or delays in achieving or achievement of less than the anticipated financial benefit from initiatives related to working capital reductions, cost reductions, employee productivity goals, and an inability to raise or sustain prices for products or services; An inability to raise or sustain prices for products or services; An inability to maintain appropriate relations with unions and employees; The inability to achieve expected results from our acquisition activities; Our ability to continue to pay cash dividends; The amount and timing of repurchases of our common shares, if any; and Other factors affecting our business beyond our control, including, without limitation, changes in the general economy, changes in interest rates and changes in the rate of inflation. • The above list of factors is not exhaustive. • We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise. Forward – Looking Statements Page 2 • This presentation includes the use of both GAAP (generally accepted accounting principles) and non-GAAP financial measures.
https://www.avient.com/industries/packaging/cosmetics-packaging/applicators
From mascara brushes to lip gloss wands, applicators are becoming more unique and specialized. How Gravi-Tech makes the difference for packaging closures in the luxury cosmetics and spirits markets How can you make the most of color, from design through processing?
https://www.avient.com/industries/consumer/consumer-discretionary/outdoor-recreation/shooting-sports
From hunting to competitive shooting to law enforcement, your customers count on you for products that lead to success. How can you make it more durable for what they face in the field? Avient can help, from concept to finished component.
https://www.avient.com/investor-center/news/avient-expects-double-digit-sales-growth-5g-applications
Material solutions from Example materials from Fiber-Line Swellcoat™ Water Blocking Yarns, Strength Members, and Ripcord Yarns for complete cable construction, protecting 5G optical fibers from damage while reducing installation and splicing times.
https://www.avient.com/industries/packaging/cosmetics-packaging/fragrance
Information on the application and use of light shield additives to protect products from light damage GLS TPEs are designed to help you stand out from your competitors with reduced appliance movement and noise How can you make the most of color, from design through processing?
https://www.avient.com/industries/building-construction
How can you capitalize on trends toward high-performance buildings, healthier living spaces, waste reduction, and elegant outdoor living spaces? We have many of the answers, from interior to exterior, residential to commercial, and more. From the Idea Center
https://www.avient.com/sites/default/files/resources/NOVEL_THERMOPLASTIC_ELASTOMERS_FOR_UNIVERSAL_OVERMOLDING_ON_DISSIMILAR_THERMOPLASTICS.pdf
The barrel temperature of the injection molding machine was set from 180°C to 220°C (360°F to 430°F) and the injection velocity from 0.7 inch/sec to 2.0 inch/sec. TPE-2 TPE-2 materials are opaque and their base chemistries are different from TPE-1. Jiren Gu and Krishna Venkataswamy, “Block Copolymer Compositions for overmolding any TPE, US patent filed, March 2004 3.
https://www.avient.com/industries/healthcare/labware-diagnostics/laboratory-equipment
Laboratory equipment used in diagnostics and research comprises a variety of devices, from Petri dishes, tubes, flasks, and slide storages to manual and automatic pipettes, spatulas, swab sticks, and PCR plates. Explore how Trilliant™ conductive formulations help solve the performance challenges for pipette tip applications Explore how Trilliant™ conductive formulations help solve the performance challenges for pipette tip applications (Chinese language version)
https://www.avient.com/industries/healthcare/drug-delivery-systems/auto-injectors-and-drug-delivery-pens
From colorants and additives that provide brand differentiation to thermoplastic elastomers that allow ergonomic designs, our solutions help optimize product performance. Learn how chemically resistant Trilliant™ HC thermoplastics and Versaflex™ HC TPEs provide enhanced durability to withstand common hospital cleaners and disinfectants Learn how Mevopur™ Healthcare Functional Additives help protect and enhance the performance of polymers used in healthcare applications
https://www.avient.com/sites/default/files/resources/Investor%2520Day%2520-%2520May%25202012%2520-%2520Global%2520Engineered%2520Materials.pdf
Nikrant Page 67 United States 36% Europe 36% Canada 2% Asia 20% Latin America 2011 Revenue: $0.6 Billion2011 Revenue: $0.6 Billion SolutionsSolutions At a Glance Appliance 6% Building & Construction 3% Wire & Cable 14% Electrical & Electronics 14%Consumer 21% Packaging 5% Industrial 8% Misc. 3% HealthCare 5% Transportation 21% America 6% 2011 Revenue by Industry Segment2011 Revenue by Industry Segment 1.1% 1.3% 3.4% 5.1% 9.6% 8.0% 12-16% 2006 2007 2008 2009 2010 2011 2015 Operating Income % of Sales Target Expanding ProfitsExpanding Profits Page 68 Value Proposition • GSEM is a global leader providing complete specialty solutions encompassing innovative technologies and services to enable customer success Transformation Highlights • Dramatic turnaround of the Engineered Materials business through mix improvement and specialty focus Value Proposition and Transformation Highlights improvement and specialty focus • GLS acquisition successfully integrated, having more than doubled earnings in 3 years • PolyOne culture and strategy now engrained worldwide • Expansion into healthcare with dedicated resources > $15B Addressable Market Page 69 • Polymer design, formulation and service expertise • Broad, global technology base and regional centers of excellence • Ten innovation centers around the world Key Differentiators • Ten innovation centers around the world • Specialty brand leadership with PolyOne, GLS, NEU and ECCOH • Ability to leverage global key account team Page 70 From Volume Commodity-driven product portfolio To Value Specialty technology and solutions EM North America Transformation Volume Sales Gross Margin $ Mix Transformation – Executing the Strategy 2006 2011 2006 2011 2006 2011 Page 71 $12 $29 Operating Income ($ in millions) • Provided access to new customers in specialized, high-growth markets such as healthcare and consumer • Strategic partner to many of the world’s best-known companies GLS Integration Success 16.9% 8.2% 2007 2011 2007 2011 Working Capital % of Sales • Complementary global footprint provided additional cross-selling opportunities • Opportunity to expand margins and drive working capital improvement while remaining customer-focused Page 72 $1.3 $27.6 2006 2011 Healthcare Revenue • Investment in dedicated healthcare team to drive penetration and growth • Leverage product portfolio globally & win specialty business Areas of Focus $10.5 $117.9 2006 2011 Consumer Revenue 2006 2011globally & win specialty business in targeted markets • Aggressively commercialize specialty innovation platforms • Utilize our innovation centers to influence OEM design (Revenue in $ millions) Page 73 • Carbon Nanotube Formulations � Applications: Semiconductor equipment, hard drives � Customer benefits: Scrap cost reduction and clean conductivity • Thermally Conductive Solutions Applications: Sockets and bulb holders for LED lighting Key Innovations � Applications: Sockets and bulb holders for LED lighting � Customer benefits: Cost reduction, energy saving, and design flexibility • FDA-Regulated TPEs � Applications: Food packaging seals, intravenous delivery systems, medical stoppers, prefilled syringes � Customer benefits: Clean and safe elastomers for highly regulated applications Page 74 Critical Imperatives and 2015 Goal Critical Imperatives • Commercialize critical new technology platforms • Manage the mix as we continue to drive the transformation • Global translation of commercial successes 2015 Goal • 12 - 16% return on sales Page 75 Page 76